Replies to post #2593 on RedHill Biopharma Ltd (RDHL)

[FRAKSTER]

CYDY A MARKET CAP OF 3 BILLION. WAS .58 IN THE PAST YEAR. NOW $5+.

[midastouch017]

RDHL does not have much market respect so
unless it shows Covid results, it is difficult to
reach there.

Foreign companies are always somewhat underpriced
in comparison with similar US companies with
similar/identical parameters.
I have noticed these phenomena countless times
over the many years i am in the stock market.

Having said that, finally as the saying goes:
"Oil will surface over water", namely if the
company proves its points(=products) the price
gap will be greatly minimised or even equalized.

As you rightly said, RDHL has 3 approved products,
plus a potential Covid drug (which so far seems very
convincing) therefore a $25 target price is quite
realistic in the not so far future.

I agree a good start towards said target price
would be with the Covid drug, while bad news
will, as you say, cause a sharp price decline.

Fingers crossed fellow longs!

:-)